Late‑stage momentum Kodiak is advancing three late‑stage retinal programs (Zenkuda, KSI‑501, KSI‑101) with positive clinical visibility and high market interest, creating multiple high‑value collaboration and licensing opportunities for ophthalmology partners, contract research organizations, and manufacturing collaborators.

Premier platform The ABC Platform™ combines antibody engineering with chemistry‑based therapies, enabling potential co‑development or licensing of bispecific and biopolymer conjugate therapies for other ocular diseases, expanding partnership avenues beyond retinal indications.

Strategic geography Headquartered in Silicon Valley with proximity to top biotech talent and investors, Kodiak is well positioned to engage strategic partners, venture funding rounds, and co‑development agreements with global biopharma seeking access to advanced retina therapeutics.

Financial runway With substantial funding ($1.2B) and multi‑year development timelines, Kodiak has the capital to pursue shared risk partnerships, milestone‑based deals, and upfronts for co‑development or exclusive geographic rights in retina programs.

Market validation Recent and upcoming clinical presentations at major ophthalmology events, plus potential non‑inferiority data to competitive anti‑VEGF therapies, offer tangible kickoff points for sales outreach to ophthalmology practices, payers, and patient advocacy groups seeking new durability and efficacy advantages.